RxDoctor Payments Data

Jose Rivera Guzman, MD

Internal Medicine · San Juan, PRNPI 1770582298

Payments from drug & device makers

$741in general payments, 2019–2025

Across 20 payments — averaging $37.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$215
  • Merck$153
  • E.r. Squibb & Sons, L.L.C.$100
  • Boehringer Ingelheim$96
  • Smith+Nephew$71
  • Sanofi-aventis U.S. LLC$65
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$741100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$741 in reported general payments places this provider in the 50th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$8,735
Medicare patients
30
Services billed
98

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Janumet XrSitagliptin Phos/Metformin Hcl30$31,803
EliquisApixaban35$27,380
JardianceEmpagliflozin27$26,139
JanumetSitagliptin Phos/Metformin Hcl23$25,366
JanuviaSitagliptin Phosphate26$22,562
JentaduetoLinagliptin/Metformin Hcl20$14,699
XareltoRivaroxaban16$10,519
TradjentaLinagliptin11$7,859
LantusInsulin Glargine,hum.Rec.Anlog53$6,785
SynthroidLevothyroxine Sodium70$5,822
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,792
Pentoxifylline29$2,277
Gabapentin130$2,187
Sucralfate24$2,145
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip56$1,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet Xr, Janumet, Januvia$153$79,73179 claims
Boehringer IngelheimJardiance, Jentadueto, Tradjenta$96$48,69658 claims
Johnson & JohnsonXarelto$215$10,51916 claims
Sanofi-aventis U.S. LLCLantus$65$6,78553 claims
AbbVieSynthroid$23$5,82270 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →